In Section A, members will acquire distinct doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Extra individuals will be enrolled on the identified monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In Phase C, https://abbv-744forsmallcelllungc24578.win-blog.com/12312492/rumored-buzz-on-abbv-744-for-small-cell-lung-cancer-research